Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

UroGen Pharma (URGN) EBIT: 2015-2024

Historic EBIT for UroGen Pharma (URGN) over the last 10 years, with Dec 2024 value amounting to -$96.8 million.

  • UroGen Pharma's EBIT fell 56.09% to -$27.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$133.4 million, marking a year-over-year decrease of 59.32%. This contributed to the annual value of -$96.8 million for FY2024, which is 47.68% down from last year.
  • Latest data reveals that UroGen Pharma reported EBIT of -$96.8 million as of FY2024, which was down 47.68% from -$65.5 million recorded in FY2023.
  • UroGen Pharma's 5-year EBIT high stood at -$65.5 million for FY2023, and its period low was -$126.7 million during FY2020.
  • Moreover, its 3-year median value for EBIT was -$79.0 million (2022), whereas its average is -$80.5 million.
  • Per our database at Business Quant, UroGen Pharma's EBIT grew by 27.18% in 2021 and then crashed by 47.68% in 2024.
  • Yearly analysis of 5 years shows UroGen Pharma's EBIT stood at -$126.7 million in 2020, then grew by 27.18% to -$92.3 million in 2021, then increased by 14.36% to -$79.0 million in 2022, then climbed by 17.09% to -$65.5 million in 2023, then tumbled by 47.68% to -$96.8 million in 2024.